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Cardiovascular complications dominate the landscape of chronic kidney diseases
(CKD). Endothelial cell dysfunction (ECD) is a well-known culprit of cardiovascular
morbidity and it develops in CKD with remarkable frequency. This brief overview of
ECD in CKD scans two decades of studies performed in my laboratory, from genetic
analyses to proteomic and metabolomics screens. I provide a detailed description of
ﬁndings related to the premature senescence of endothelial cells, cell transition
from the endothelial to mesenchymal phenotype, and stages of development of
ECD. Clinical utility of some of these ﬁndings is illustrated with data on laser-
Doppler ﬂowmetry and imaging in patients with CKD. Some currently available and
emerging therapeutic options for the management of ECD are brieﬂy presented.
Copyright & 2015. The Korean Society of Nephrology. Published by Elsevier. This is an
open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
The ﬁrst usage of the term “endothelial dysfunction” was
related to the pulmonary circulation in bleomycin-induced pul-
monary ﬁbrosis [1]. The term received its modern meaning with
the publication of a study of impaired acetylcholine-induced
vasorelaxation of coronary arteries in patients with coronary athe-
rosclerosis [2]. However, this paradoxical vasoconstrictor response
to acetylcholine reﬂected only one of multiple functions of
endothelial cells (ECs), and the term was further broadened to
acknowledge the fact that in the case of EC dysfunction (ECD)
abnormalities may occur in any of the functions carried out by
these cells, as depicted in Fig. 1. The contribution of dysfunctional
vascular endothelium to the development and progression of
various diseases, including renal diseases, is difﬁcult to over-
estimate [3]. However, this cell type has long been ignored by
nephrologists. Only recently the attention of nephrologists has
been attracted to these cells endowed with a multitude of15. The Korean Society of Nep
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(MS Goligorsky).functions, such as the regulation of hemodynamics, permeability,
nutrient exchange, ﬂux of inﬂammatory leukocytes, pro- and
anticoagulant functions, amongst others. Therefore, dysfunction of
this cell type has a myriad of consequences, as illustrated in Fig. 1.
Multiple lines of evidence indicate that cardiovascular morbid-
ity and mortality dominate the landscape of chronic kidney
diseases (CKD) long before they enter the end stage. ECD is a
well-known instigator of cardiovascular morbidity and it develops
in CKD with a remarkable frequency. Flow-dependent relaxation
of conduit vessels, a function of endothelium-derived relaxing fac-
tors, mainly nitric oxide (NO) production, is suppressed in patients
and animals with CKD. Different modiﬁcations of testing end-
othelium-dependent vasorelaxation have become the standard
for diagnosing ECD, together with other surrogate biomarkers
such as markers of oxidative stress [8-iso-prostaglandin F2-alpha
and oxidized low-density lipoprotein (LDL)], proinﬂammatory
markers (high-sensitivity C-reactive protein, lipoprotein-
associated phospholipase A2, soluble intercellular adhesionhrology. Published by Elsevier. This is an open access article under the
3, New York Medical College, Valhalla, NY 10595 USA.
Figure 1. An “airport hub” model of endothelial functions. In this model, all functions are intrinsically interconnected, and any impairment of one
would affect the others. Some essential mediators of these functions are shown in brackets. Pathophysiological consequences of endothelial
dysfunction are depicted at the perimeter.
EDHF, endothelium-derived hyperpolarizing factor; EDRF, endothelium-derived relaxing factor; HTN, hypertension; MCP, monocyte chemotactic protein; NO,
nitric oxide; PA, plasminogen activator; PAI-1, plasminogen activator inhibitor-1; prot, protein; TF, tissue factor; VSM, vascular smooth muscle.
Note. From “Endothelial cell dysfunction: can’t live with it, how to live without it,” by M.S. Goligorsky, 2005, Am J Physiol Renal Physiol, 288, p. F871. Copyright
2005, The American Physiological Society. Reprinted with permission.
Figure 2. Summary of homocysteine-induced molecular pathways
predisposing to development of endothelial dysfunction.
CYP, cytochrome P; ET-1, endothelin-1; EDHF, endothelium-derived hyper-
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endothelial NO synthase (eNOS) asymmetric dimethylarginine
(ADMA), circulating procoagulants, and others [4]. Diverse tradi-
tional risk factors for cardiovascular disease are joined by non-
traditional risk factors, such as ADMA, advanced glycation end-
products, pro-oxidants, all accumulating in CKD, conspire to
induce ECD via its most reliable attribute, eNOS uncoupling,
which results not only in the downregulation of NO production,
but also generates oxygen free radicals. The pathogenic mechan-
isms of developing ECD and ensuing cardiovascular morbidity
have been the focus of studies in my laboratory for the past more
than two decades. Here, I would like to present a retrospective of
these studies, some accomplishments in deciphering molecular
mechanisms of ECD, and some inevitable shortcomings.polarizing factor; eNOS, endothelial nitric oxide synthase; HMGCoAR,
3-hydroxy-3methylglutaryl coenzyme A reductase; NCK, an adaptor protein;
PECAM, CD31.
Note. From “Endothelial cell dysfunction: can’t live with it, how to live
without it,” by M.S. Goligorsky, 2005, Am J Physiol Renal Physiol, 288,
p. F871. Copyright 2005, The American Physiological Society. Reprinted with
permission.Screening cardiovascular-relevant genes
A cardiovascular gene screen of ECs with inhibited or
uncoupled eNOS or elevated ambient concentration of homo-
cysteine, two nontraditional mediators of ECD highly prevalent
in patients with CKD, revealed that this condition is associated
with the modulation of the expression of several genes, as
detailed in Fig. 2, 3.
One of the pursued leads obtained from this survey was related
to the upregulation of the receptor for oxidized LDL, lectin-like
oxidized low-density lipoprotein receptor-1 (LOX-1) [5]. LOX-1
was induced not only in macrophages, but also in ECs cultured in
the presence of NOS inhibitors. This increased LOX-1 expression
was associated in ECs with cellular uptake of ﬂuorescently labeled
oxidized LDL, which was reduced two- to three-fold by coincuba-
tion with a competitive inhibitor, soluble LOX-1, and in suppres-
sion of NO production. In cultured macrophages ADMA-induced
overexpression of LOX-1 was associated with accumulation of
oxidized LDL and accelerated formation of “foam” cells.Induction of 3-hydroxy-3-methylglutaryl coenzyme A
reductase by exposure of macro- and renal microvascular ECs
to homocysteine was conﬁrmed at the level of protein expres-
sion. Gas chromatography–mass spectrometry analyses of
dysfunctional ECs revealed increased loading with cholesterol,
a conditioned which we termed “endothelial lipidosis” (by
analogy with the hepatic lipidosis) [6]. Coapplication of a
statin resulted in the normalization of cellular cholesterol
and improved NO-mediated vasorelaxation.
Homocysteine-induced upregulation and redistribution of a
gap-junctional protein connexin-43 (Cx-43) did not show any
increase in cell-to-cell gap junctional communication. Confocal
microscopy of stressed ECs expressing chimeric Cx-43 green
Figure 3. Summary of asymmetric dimethylarginine-induced molecu-
lar pathways predisposing development of endothelial dysfunction.
LOX-1, lectin-like oxidized low-density lipoprotein receptor-1; SOD,
superoxide dismutase.
Note. From “Endothelial cell dysfunction: can’t live with it, how to live
without it,” by M.S. Goligorsky, 2005, Am J Physiol Renal Physiol, 288,
p. F871. Copyright 2005, The American Physiological Society. Reprinted
with permission.
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plasmic reticulum ﬂuorescent markers revealed a profound
redistribution of Cx-43 from the plasma membrane to the mito-
chondria. In view of the fact that Cx-43 is the main endothelial-
smooth muscle cells gap junctional protein for delivery of
endothelial hyperpolarizing factor, we tested non–NO-mediated
vasorelaxation in microdissected renal interlobar arteries and
demonstrated the perturbed transmission of endothelium-
derived hyperpolarizing factor to vascular smooth muscle cells [7].
One of the reasons the search for the mechanisms of ECD is
important lies in the ﬁnding that the inhibition of NOS renders
ECs to undergo endothelial-to-mesenchymal transition (Endo-MT)
[8]. This in turn leads to microvascular rarefaction, elongation of
distances for oxygen diffusion to tissues, and underlies the
development of tissue hypoxia. These observations and conclu-
sions were furthered by studies from Zeisberg et al [9] who
examined this process in different models of CKD, and Li et al [10]
who documented it in experimental type 1 diabetes. Increased
synthesis of collagen XVIII [8,11] and accumulation of its anti-
angiogenic fragment, endostatin, were documented in vivo and
in vitro after inhibition of eNOS. Endostatin treatment of ECs in
culture was found to suppress the expression of endothelial
markers and enhance expression of mesenchymal markers. In
vivo studies conﬁrmed actuation of Endo-MT [8], as a step toward
microvascular rarefaction, tissue hypoxia, and eventual ﬁbrosis.
All these pathways could potentially accelerate atherogenic
remodeling of the vascular wall, thus contributing to the elevated
cardiovascular morbidity of patients with CKD, as detailed in
earlier publications [11,12]. Other ﬁndings still remain unexplored.Figure 4. Summary of major functional and metabolomic ﬁndings
and proposed pathways of L-glutamine (GLN) supplementation-
induced amelioration of vascolopathy. See the text for details. eNOS,
Endothelial nitric oxide synthase.Proteomic abnormalities of dysfunctional ECs
ECD is associated with profound metabolic abnormalities;
these not only can initiate ECD, but also tend to aggravate
preexisting ECD. Addabbo et al [13] used two-dimensional elec-
trophoresis, in-gel digestion, and mass-spectrometry analysis to
screen renal microvascular isolates obtained from mice with
inhibited eNOS. Data revealed 13 nonredundant differentially
expressed proteins with a high level of conﬁdence. Five of thoseare speciﬁc for mitochondria, and two downregulated proteins are
known components of the Krebs cycle: aconitase-2 and enoyl-
coA-hydratase-1 [13]. This deﬁciency of key enzymes of tricar-
boxylic acid cycle is associated with reduced mitochondrial mass,
mitochondrial oxidative stress, and switch to the normoxic
glycolysis (Warburg type of metabolic hypoxia seen in chronic
uncoupling of eNOS) to support energy metabolism. In collabora-
tive studies with Stoessel et al [14] we demonstrated that in this
model of ECD induced by L-NG-monomethylarginine, acetate salt
(L-NMMA), renal tissue hypoxia is undetectable further indicating
towards normoxic glycolysis. We also observed accumulation of
lactate, which conﬁrms the fact that glycolysis is enhanced in ECD.
Moreover, by supplying cultured cells with the metabolic inter-
mediate downstream of the deﬁcient aconitase-2-α-ketoglutarate
(which enters the Krebs cycle bypassing the enzymatic bottleneck)
it becomes possible to restore energy metabolism and prevent cell
death or premature senescence. These ﬁndings raise the question
whether it could be possible to restore EC metabolism in ECD by
supplementing animals with L-glutamine (GLN).Metabolic abnormalities in ECD
Addabbo et al [15] addressed this question in the follow-up
metabolomic studies of isolated renal microvasculature and plasma
of mice chronically receiving an eNOS uncoupler with and without
GLN supplementation. Analysis of the metabolome of renal micro-
vasculature detected 1,400 aligned features by untargeted molecu-
lar feature extraction; 37 differential metabolites in L-NMMAþGLN
versus L-NMMA and control versus L-NMMA were shared. L-
NMMA-induced renal microvascular metabolite changes that were
offset by GLN supplementation include myoinositol, GPC, betaine,
and taurine. The latter was the only osmolyte upregulated in L-
NMMA-treated mice (in contrast with the downregulation of GPC,
betaine, and myoinisitol) and compensated with GLN treatment.
GABA and alanine, potential inhibitors of taurine transport, were
also downregulated in L-NMMA treated mice.
Treatment with GLN supplementation results in improved
vasculopathy (as judged by restored endothelium-dependent
vasorelaxation) and decreased proteinuria [15], as summarized
in Fig. 4. In addition, metabolomic studies conducted using liquid
chromatography–mass spectrometry analyses disclose multiple
metabolite abnormalities developing in ECD and restored by
GLN supplementation. Among those are lysophospholipids, hip-
puric acid (all elevated), and GLN/glutamate itself (reduced levels),
which become normalized after GLN supplementation [15].
Hence, metabolic abnormalities affect EC functions and correcting
these abnormalities leads to the amelioration of ECD and vasculo-
pathy, both contributing to progression of CKD.
Presently, the mechanism(s) of GLN action are left for specula-
tion. The previously described contribution of GLN to glutathione
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source of reducing equivalents, like nicotinamide adenine dinu-
cleotide phosphate (NADPH), is highly relevant to the present
dataset. A similar effect is observed in erythrocytes, where GLN
plays a role of antioxidant and preserves NADPH level required for
glutathione recycling. Consistent with our previous demonstration
of enhanced oxidative stress in the L-NMMA model of ECD [14],
this antioxidant defense by GLN supplementation can explain
some of the observed beneﬁts of such a therapy: prevention of
eNOS uncoupling and generation of peroxynitrite. An additional
potential mechanism of beneﬁcial vascular effect of GLN supple-
mentation can be the consequence of restored Krebs cycling of
intermediates with the activation of malate shuttle and enhanced
production of NADPH, a cofactor of eNOS. Furthermore, the ability
of GLN to be converted to L-citrulline, with the latter converted to
L-arginine, may underlie the observed restoration of endothelium-
dependent vasorelaxation. Such a necessity may present itself
in situations accompanied by uncoupling of eNOS, as it occurs in
cultured porcine aortic ECs where L-NMMA stimulated L-arginine
efﬂux via a yþ transporter, potentially depleting its intracellular
pool and further exacerbating eNOS uncoupling [15].
Another totally unexpected ﬁnding of this metabolomic ana-
lysis is related to the elevated levels of hippurate in L-NMMA-
treated mice with ECD, but without uremia. Hippuric acid is a
well-known “uremic toxin”. In patients with CKD, the level of
hippuric acid is increased from 2.2μM in controls to 160μM in far-
advanced disease. Hippurate inhibits glucose utilization in striated
muscles, thus contributing to muscle weakness, and has been
suggested to accelerate the progression of CKDs. To examine the
potential effects of hippuric acid on vasomotion, we employed
thoracic aorta rings to study its vasoconstrictor effects and its
inﬂuences on vasorelaxation. Addition of hippuric acid at con-
centrations of 100 mm to 1mM to the incubation bath did not
produce vasoconstriction. In contrast, hippuric acid signiﬁcantly
and dose-dependently attenuated acetylcholine-induced relaxa-
tion of aortic rings. These ﬁndings establish an unknown action of
hippuric acid, a putative “uremic toxin”, to alter vasorelaxation.
These observations provide a potential link between the accumu-
lation of hippuric acid, even in preuremic animals, and the early
development of vasculopathy [15].
As the renal excretion of hippurate represents the major
pathway for its elimination, the ﬁnding of its elevation in our
nonuremic mice displaying only mild renal impairment was
rather unexpected. These ﬁndings may argue in favor of the
increased metabolic rate of hippurate synthesis during syn-
dromes associated with ECD. The above lines of investigation
would require further studies.Premature EC senescence in CKD
The role of telomere attrition and cell senescence in aging and
diseased kidney has been pioneered in a series of studies
performed by Melk and Halloran [16]. Studies in my laboratory
[17–20] revealed that stress-induced premature senescence (SIPS)
of ECs occurs even in the presence of relatively unaffected telo-
meres. Diverse stress signals, such as pro-oxidants, ADMA, none-
nzymatically glycation-modiﬁed proteins induce cell cycle arrest,
SIPS, and eventual apoptosis in low-passage cultured cells and in
young mice. Notably, SIPS can be reversed after the withdrawal of
the offending stressor; however, if the stressor persists, SIPS
becomes irreversible, ECs may undergo apoptosis, eventually
culminating in microvascular rarefaction.Senescent ECs not only disrupt the function of the endothelial
lining of the vessels, but also affect the neighboring cells by their
secretome, collectively designated as senescence-associated secre-
tory products, which contain transforming growth factor-alpha
(TGF-α) galectin-3, insulin-like growth factor protein-3 (IGFBP-3),
IGFBP-4 and IGFBP-6, macrophage inhibitory cytokine-1 [21].
Dysfunctional senescent ECs release collagen XVIII also, which is
cleaved to yield its C-terminal antiangiogenic fragment, endostatin
[8]. High-resolution mass spectrometry analysis of the secretome
of endothelial progenitor cells disclosed 133 proteins, some known
as membrane-bound, others known as secreted [22]. Speciﬁcally,
soluble forms of vascular endothelial growth factor receptors,
adhesion molecules, semaphorin 3F and TGF-β, CD109, members
of roundabout (robo) family, as well as endothelial markers were
detected. Mass spectrometry screen of the secretome of colony-
forming units, precursors of mature ECs, identiﬁed 272 nonre-
dundant proteins of which 124 were also found in cultured
endothelial progenitor cells [23]. Secretory products included
matrix metallopeptidase-9, interleukin-8, migration inhibitory
factor, various cathepsins and protease inhibitors, S100 proteins
A11, A8 and A4, plasminogen activator inhibitor-2 and apolipo-
protein E, as well as a proangiogenic and prosurvival factor,
thymidine phosporylase. These investigations explain the growing
interest in “cell-free therapy”; several ongoing clinical trials,
conducted mostly in patients with cardiovascular disease, are
underway. Along the same lines of inquiry, Matsumoto et al in our
laboratory used the cell-free extract of endothelial progenitor cells
to treat activated ﬁbroblasts (myoﬁbroblasts) and discovered that
this cell-free therapy prevented TGFβ1-induced ﬁbroblast activa-
tion. In vivo injection of this cell-free extract subcapsularly in
ﬁbrotic kidneys prevented and reversed development of ﬁbrosis in
the mouse models of unilateral ureteral obstruction and chronic
phase of folic acid-associated nephropathy (unpublished data).
The role of microRNAs in promoting organ ﬁbrosis (ﬁbro-
miRs) is rapidly expanding [24]. A list of ﬁbromiRs includes
miR-15 family, miR-21, miR-34a, miR-192, miR-199b, miR-208;
whereas other miRs exhibit antiﬁbrotic signaling, such as miR-
1, miR-24, miR-29b, miR-101, miR-200b, among others.
Regeneration of microvasculature is further impaired by the
production of antiangiogenic substances, like endostatin, and
developing incompetence of endothelial progenitor cells. In
addition, obliteration of microvasculature occurs via the pro-
cess of Endo-MT, as discussed below.Screening patients with CKD for subclinical signs of ECD
Various direct and indirect tests are used clinically to diag-
nose ECD. I have previously summarized some of those by
reviewing individual diagnostic modalities [4]. Obviously, early
preclinical diagnosis of ECD, before cardiovascular complications
become overt, is the main goal of such a screening. Diverse
surrogate markers of ECD have been established: levels of ADMA,
homocysteine, markers of oxidative stress and inﬂammation,
endothelial microparticles, among others, all have place in diag-
nosis. Functional testing of endothelial function can provide a
direct unambiguous quantitative measure of the severity of ECD.
Functional tests include measurement of ﬂow-mediated vasodila-
tion, cutaneous laser-Doppler ﬂowmetry and imaging, measure-
ment of aortic stiffness and pulse wave propagation, carotid
intima-media thickness, and other techniques. We used laser-
Doppler ﬂowmetry and imaging to interrogate cutaneous micro-
vasculature (which incidentally has some commonalities with
Kidney Res Clin Pract 34 (2015) 76–8280renal microvasculature) in its adaptation to a short period of
occlusion and thermal stimulation [25,26]. These studies demon-
strated that abnormal reactive hyperemic responses to tourniquet
occlusion or to thermal stimulation, so typical of patients with
end-stage kidney disease with the concomitant cardiac disease or
diabetes mellitus, are also observed in approximately one-half of
these patients with no clinical history of cardiovascular disease or
diabetes mellitus. The follow-up study compared these para-
meters with the risk assessment using Framingham and Cardiorisk
scores. It showed that abnormal parameters of laser-Doppler
ﬂowmetry testing were associated with increased cardiovascular
mortality, but Framingham and Cardiorisk scores, as well as levels
of homocysteine or C-reactive protein had lesser predictive power.
Collectively, these studies [25,26] re-emphasized the importance
of ECD in the development of cardiovascular morbidity and
mortality, and the necessity to test patients with CKD for signs
of silent, preclinical ECD. Such testing is an important complement
to Framingham and Cardiorisk scoring of cardiovascular risk.Endo-MT and the role of TGF-β and endostatin signaling
Endo-MT is a physiological developmental stage occurring
during embryonic formation of heart valves and septa. In adult-
hood, Endo-MT is a sizable contributor to vascular drop-out and
development of tubulointerstitial ﬁbrosis, as has been described in
three different models of renal disease—unilateral ureteral
obstruction, streptozotocin-induced diabetic nephropathy, and a
mouse model of Alport’s syndrome [9,10]. From 30% to 50% of
interstitial ﬁbroblasts were found to originate from the endothe-
lium. TGF-β is a major mediator of Endo-MT, and BMP-7 is a factor
counteracting Endo-MT as demonstrated using the EC fate-tracing
technique. Actions of TGF-β are mediated via activin receptor-like
kinases 1 and 5 (Alk1 and Alk5). Activation of Alk1 selectively
expressed on ECs results in cell migration, proliferation, and
angiogenesis, whereas stimulation of Alk5 induces, via Smads 2/
3 phosphorylation, the transcription of SM22α, ﬁbronectin, and
plasminogen activator inhibitor-1 which mediate differentiation
along the smooth muscle/mesenchymal phenotype and leads to
formation of myoﬁbroblasts. The balance between activation of
these two Alk pathways is regulated by endoglin, another speciﬁc
endothelial TGF coreceptor. Notably, prolonged activation with
TGF-β results in the escape of Alk1 signaling and predominant
signaling via Alk 5, thus promoting Endo-MT [27].
Gene microarray analysis of cultured ECs treated with an
inhibitor of NOS revealed upregulation of collagen XVIII and its
antiangiogenic fragment endostatin, a ﬁnding conﬁrmed
in vivo in mice chronically treated with NOS inhibitor [8].
Enhanced generation of endostatin in these animals leads to
the development of Endo-MT and eventual rarefaction of renal
microvasculature, thus further compounding vascular and
parenchymal pathology. As mentioned above, ECs exposed to
diverse stressors respond with lysosomal dysfunction, leakage
of cathepsins, and degradation of SIRT1. In turn, SIRT1 deple-
tion leads to the downregulation of MMP-14 and the accumu-
lation of ECM.Therapeutic options
Some well-established therapeutic interventions are sum-
marized below [28].Inhibition of angiotensin-2 action
This is the mainstay therapy directed to slow down the pro-
gression of CKD. It uses ACE inhibitors and angiotensin
receptor blockers, which exert their action through inhibition
of NADPH oxidase, preservation of eNOS function, and brady-
kinin level, thus improving ECD.
3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors
These are important contributors to the treatment of ECD.
Statins elicit their effect on ECs by reducing oxidative stress
and improving eNOS function, both occurring independent of
their lipid-lowering effects.
Peroxisome proliferator-activated receptor alpha agonists
Fibrates, improve EC function by reducing oxidative stress
and nuclear factor kappa B activation.
Antioxidants
Tempol and ebselen, protect endothelium by preventing
excessive accumulation of reactive oxygen species thus redu-
cing eNOS uncoupling and restoring endothelial functions.
Several rational experimental strategies for vascular protec-
tion have recently emerged. These are brieﬂy noted below.
An activator of the antioxidant Kelch-like ECH-associated
protein 1 (Keap1)-Nuclear factor (erythroid-derived 2)-like 2
(Nrf2) pathway
This is a synthetic triterpenoid bardoxolone methyl, has
been advocated as a potential therapeutic agent restoring ECD
[29] and improving renal function in CKD patients with type
2 diabetes [30]. The recent “BEACON” clinical trial of Bardox-
olone methyl, an Nrf2 activator, however, cast some doubt in
its efﬁcacy at least in patients with type 2 diabetes and stage
4 CKD [31].
An endogenous antioxidant, lipoic acid
This may play a role in vascular and renal protection against
elevated levels of angiotensin II-induced injury, as has been
demonstrated in transgenic rats harboring human renin and
angiotensinogen genes [32]. However, in a prospective, pla-
cebo-controlled, double-blind clinical trial of α-lipoic acid in
combination with tocopherols did not inﬂuence biomarkers of
inﬂammation and oxidative stress or the erythropoietic
response in hemodialysis patients [33].
Mammalian target of rapamycin inhibitor
Rapamycin and a variety of recently synthesized more
potent inhibitors, may improve ECD by preventing (SIPS)
of ECs.
Activators of sirtuins
Resveratrol and newly developed analogs, may have a place
among therapeutic approaches to prevent EC senescence and
restore metabolic abnormalities.
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This remains at the experimental stage [15], but pilot
clinical trials are being initiated.
Suppression of the JNK pathway
This can be achieved through activation of adenosine mono-
phosphate kinase by chronic treatment with 5-aminoimidazole-4-
carboxamide 1-β-D-ribofuranoside, Acadesine, N1-(β-D-ribofurano-
syl)-5-aminoimidazole-4-carboxamide or metformin [34]. Their
effects are mediated via activation of peroxisome proliferator-
activated receptor gamma coactivator 1-alpha and improved
mitochondrial biogenesis and cytoprotection, thus leading to
attenuation of oxidative stress-induced endothelial injury.Conﬂict of interest
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